Category: AngioDynamics Inc.
AngioDynamics reports a profitable fiscal 3rd quarter and nearly doubles Wall Street's earnings forecast, but shares slide anyway.
AngioDynamics (NSDQ:ANGO) put some black ink in the ledger during its fiscal 3rd quarter and handily topped Wall Street's earnings forecast, but investors have remained unmoved, sending ANGO shares down 12% since its April 9 earnings release.
AngioDynamics wins a nearly $75 million judgment against erstwhile partner Biolitec AG over an alleged scheme to evade U.S legal jurisdiction.
New York's AngioDynamics wins updated labeling from FDA regulators, indicating its AngioVac venous drainage system for up to 6 hours at a time.
AngioDynamics (NSDQ:ANGO) tallied a new win for its AngioVac drainage system, with new FDA clearance to market the device for extended use.
New York's AngioDynamics lands FDA clearance for a new BioFlo product and takes charge of distribution partner Medcomp's Celerity tip locater after an FDA loss.
Biolitec AG appeals a Massachusetts federal judge's issuance of an arrest warrant for its CEO and a $63 million sanction in its legal war with AngioDynamics.
New York's AngioDynamics closes the books on an employee discrimination lawsuit with neither party admitting wrongdoing.
Medtech maker AngioDynamics (NSDQ:ANGO) finally put to bed a former employee's discrimination lawsuit, ending the quarrel with neither party admitting to any wrongdoing.
AngioDynamics posts a loss for its fiscal 2nd quarter, but its stock gains on an earnings beat and a boost for the low end of its full-year sales guidance.
AngioDynamics (NSDQ:ANGO) shares are up a tad today after the medical device company beat Wall Street's expectations with its fiscal 2nd-quarter earnings.